Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price Target & Predictions
ALNY Stock Forecast
Alnylam Pharmaceuticals stock forecast is as follows: an average price target of $250.16 (represents a -5.70% downside from ALNY’s last price of $265.27) and a rating consensus of 'Buy', based on 21 wall street analysts offering a 1-year stock forecast.
ALNY Price Target
ALNY Analyst Ratings
Alnylam Pharmaceuticals Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Aug 27, 2024 | Kostas Biliouris | BMO Capital | $300.00 | $269.31 | 11.40% | 13.09% |
Aug 26, 2024 | Luca Issi | RBC Capital | $300.00 | $271.43 | 10.53% | 13.09% |
Aug 16, 2024 | Salveen Richter | Goldman Sachs | $370.00 | $262.70 | 40.85% | 39.48% |
Jul 08, 2024 | Whitney Ijem | Canaccord Genuity | $357.00 | $253.86 | 40.63% | 34.58% |
Jun 28, 2024 | Esther Rajavelu | UBS | $288.00 | $247.00 | 16.60% | 8.57% |
Jun 27, 2024 | Luca Issi | RBC Capital | $265.00 | $245.17 | 8.09% | -0.10% |
Jun 27, 2024 | Paul Matteis | Stifel Nicolaus | $295.00 | $247.40 | 19.24% | 11.21% |
Jun 25, 2024 | Liisa Bayko | Evercore ISI | $260.00 | $222.90 | 16.64% | -1.99% |
Jun 25, 2024 | Luca Issi | RBC Capital | $250.00 | $222.90 | 12.16% | -5.76% |
Jun 24, 2024 | Andrew Galler | Morgan Stanley | $250.00 | $224.70 | 11.26% | -5.76% |
Alnylam Pharmaceuticals Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 3 | 12 | 14 |
Avg Price Target | $323.33 | $298.50 | $289.36 |
Last Closing Price | $265.27 | $265.27 | $265.27 |
Upside/Downside | 21.89% | 12.53% | 9.08% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 03, 2024 | Oppenheimer | Perform | Perform | Hold |
Sep 03, 2024 | Wolfe Research | Negative | Negative | Hold |
Sep 03, 2024 | Cowen & Co. | Buy | Buy | Hold |
Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Sep 03, 2024 | Barclays | Overweight | Overweight | Hold |
Aug 27, 2024 | BMO Capital | Outperform | Outperform | Hold |
Aug 26, 2024 | RBC Capital | Outperform | Outperform | Hold |
Aug 16, 2024 | Goldman Sachs | Neutral | Buy | Upgrade |
Aug 02, 2024 | RBC Capital | Outperform | Outperform | Hold |
Aug 02, 2024 | Barclays | Overweight | Overweight | Hold |
Alnylam Pharmaceuticals Financial Forecast
Alnylam Pharmaceuticals Revenue Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $750.53M | - | $319.29M | $335.04M | $264.31M | - | $213.26M | $258.54M | $187.63M | $220.55M | $177.57M | $163.56M | $125.85M | $103.96M | $99.48M | $71.68M | $70.06M |
Avg Forecast | $947.97M | $898.63M | $774.48M | $730.99M | $756.71M | $654.76M | $572.26M | $544.45M | $554.21M | $527.81M | $447.22M | $428.01M | $436.92M | $396.76M | $332.28M | $312.27M | $313.13M | $291.66M | $255.56M | $240.95M | $233.61M | $218.72M | $192.05M | $168.50M | $146.64M | $119.05M | $98.76M | $91.74M | $71.60M | $57.17M |
High Forecast | $1.05B | $996.51M | $858.84M | $810.61M | $839.13M | $726.07M | $634.58M | $603.75M | $614.57M | $580.76M | $495.93M | $474.62M | $483.30M | $647.63M | $368.47M | $346.28M | $347.24M | $323.42M | $255.56M | $271.95M | $263.67M | $246.86M | $216.77M | $190.18M | $165.51M | $134.37M | $111.47M | $103.55M | $80.81M | $64.53M |
Low Forecast | $825.41M | $782.46M | $674.36M | $636.49M | $658.89M | $570.11M | $498.28M | $474.06M | $482.56M | $499.51M | $389.40M | $372.67M | $371.99M | $327.97M | $289.32M | $271.90M | $272.65M | $253.95M | $255.56M | $226.57M | $219.67M | $205.67M | $180.59M | $158.45M | $137.89M | $111.95M | $92.87M | $86.27M | $67.33M | $53.76M |
# Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 13 | 6 | 7 | 12 | 7 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.89% | - | 1.02% | 1.07% | 0.91% | - | 0.89% | 1.11% | 0.86% | 1.15% | 1.05% | 1.12% | 1.06% | 1.05% | 1.08% | 1.00% | 1.23% |
Alnylam Pharmaceuticals EBITDA Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 13 | 6 | 7 | 12 | 7 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $213.87M | - | $-143.41M | $-177.11M | $-234.69M | - | $-142.59M | $-202.03M | $-140.74M | $-132.75M | $-143.90M | $-194.20M | $-204.95M | $-132.88M | $-159.16M | $-254.57M | $-181.39M |
Avg Forecast | $-725.55M | $-687.79M | $-592.77M | $-559.48M | $-579.17M | $-501.13M | $-437.99M | $-416.70M | $-424.18M | $-403.97M | $-342.29M | $-207.18M | $-334.40M | $-303.67M | $-254.31M | $-188.35M | $-239.66M | $-151.40M | $-195.60M | $-171.23M | $-291.55M | $-137.64M | $-139.46M | $-155.94M | $-166.32M | $-147.75M | $-157.19M | $-188.16M | $-232.34M | $-202.53M |
High Forecast | $-631.75M | $-598.87M | $-516.13M | $-487.15M | $-504.29M | $-436.35M | $-381.37M | $-362.83M | $-369.34M | $-382.31M | $-298.04M | $-165.75M | $-284.71M | $-251.02M | $-221.44M | $-150.68M | $-208.68M | $-121.12M | $-195.60M | $-136.98M | $-233.24M | $-110.11M | $-111.57M | $-124.75M | $-133.05M | $-118.20M | $-125.75M | $-150.53M | $-185.87M | $-162.02M |
Low Forecast | $-804.57M | $-762.70M | $-657.33M | $-620.42M | $-642.25M | $-555.72M | $-485.69M | $-462.09M | $-470.38M | $-444.50M | $-379.57M | $-248.62M | $-369.90M | $-495.67M | $-282.01M | $-226.02M | $-265.77M | $-181.68M | $-195.60M | $-205.47M | $-349.86M | $-165.16M | $-167.36M | $-187.13M | $-199.58M | $-177.30M | $-188.63M | $-225.79M | $-278.80M | $-243.04M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.70% | - | 0.76% | 0.74% | 1.55% | - | 0.83% | 0.69% | 1.02% | 0.95% | 0.92% | 1.17% | 1.39% | 0.85% | 0.85% | 1.10% | 0.90% |
Alnylam Pharmaceuticals Net Income Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 13 | 6 | 7 | 12 | 7 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $147.75M | - | $-174.10M | $-207.49M | $-405.92M | - | $-240.34M | $-258.46M | $-204.51M | $-189.56M | $-200.29M | $-243.54M | $-253.29M | $-179.23M | $-182.22M | $-276.19M | $-208.53M |
Avg Forecast | $100.69M | $93.16M | $22.39M | $2.83M | $1.87M | $-66.35M | $-102.77M | $-105.18M | $-110.11M | $-115.01M | $-135.23M | $-265.52M | $-150.35M | $-183.21M | $-190.84M | $-241.39M | $-235.63M | $-203.47M | $-199.94M | $-219.44M | $-150.86M | $-184.97M | $-184.73M | $-202.61M | $-197.88M | $-173.95M | $-197.77M | $-208.25M | $-245.08M | $-220.80M |
High Forecast | $114.95M | $106.35M | $25.56M | $3.23M | $2.14M | $-55.20M | $-85.50M | $-87.50M | $-91.60M | $-43.70M | $-112.50M | $-212.42M | $6.26M | $90.26M | $-158.77M | $-193.11M | $-196.03M | $-162.78M | $-199.94M | $-175.55M | $-120.68M | $-147.98M | $-147.78M | $-162.09M | $-158.30M | $-139.16M | $-158.22M | $-166.60M | $-196.07M | $-176.64M |
Low Forecast | $83.77M | $77.50M | $18.63M | $2.35M | $1.56M | $-75.74M | $-117.32M | $-120.07M | $-125.70M | $-163.31M | $-154.37M | $-318.63M | $-385.90M | $-261.35M | $-217.87M | $-289.66M | $-268.99M | $-244.17M | $-199.94M | $-263.33M | $-181.03M | $-221.97M | $-221.68M | $-243.13M | $-237.45M | $-208.74M | $-237.32M | $-249.90M | $-294.10M | $-264.96M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.81% | - | 0.72% | 0.88% | 1.99% | - | 1.10% | 1.71% | 1.11% | 1.03% | 0.99% | 1.23% | 1.46% | 0.91% | 0.88% | 1.13% | 0.94% |
Alnylam Pharmaceuticals SG&A Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 13 | 6 | 7 | 12 | 7 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $199.18M | - | $183.66M | $210.34M | $235.86M | - | $154.47M | $186.38M | $142.07M | $145.32M | $146.86M | $166.29M | $167.47M | $127.90M | $126.76M | $156.28M | $120.35M |
Avg Forecast | $1.00B | $950.18M | $818.91M | $772.93M | $800.12M | $692.32M | $605.08M | $575.68M | $586.00M | $558.08M | $472.88M | $170.66M | $461.98M | $419.52M | $351.34M | $155.14M | $331.10M | $141.35M | $270.22M | $141.04M | $108.79M | $128.50M | $141.62M | $148.56M | $135.11M | $115.01M | $104.43M | $97.00M | $75.71M | $60.45M |
High Forecast | $1.11B | $1.05B | $908.10M | $857.11M | $887.27M | $767.73M | $670.99M | $638.38M | $649.83M | $614.07M | $524.38M | $204.79M | $511.02M | $684.78M | $389.60M | $186.17M | $367.16M | $169.62M | $270.22M | $169.25M | $130.54M | $154.20M | $169.94M | $178.27M | $162.13M | $138.01M | $117.87M | $109.49M | $85.45M | $68.23M |
Low Forecast | $872.77M | $827.35M | $713.04M | $673.00M | $696.68M | $602.82M | $526.86M | $501.26M | $510.25M | $528.17M | $411.74M | $136.53M | $393.33M | $346.78M | $305.92M | $124.11M | $288.29M | $113.08M | $270.22M | $112.83M | $87.03M | $102.80M | $113.30M | $118.85M | $108.09M | $92.01M | $98.20M | $91.22M | $71.19M | $56.84M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.47% | - | 1.18% | 0.64% | 1.67% | - | 1.10% | 1.71% | 1.11% | 1.03% | 0.99% | 1.23% | 1.46% | 1.22% | 1.31% | 2.06% | 1.99% |
Alnylam Pharmaceuticals EPS Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 13 | 6 | 7 | 12 | 7 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.18 | - | $-1.40 | $-1.68 | $-3.32 | - | $-2.00 | $-2.16 | $-1.72 | $-1.61 | $-1.71 | $-2.09 | $-2.18 | $-1.56 | $-1.62 | $-2.47 | $-1.92 |
Avg Forecast | $0.79 | $0.74 | $0.18 | $0.02 | $0.01 | $-0.52 | $-0.81 | $-0.83 | $-0.87 | $-0.91 | $-1.07 | $-1.12 | $-1.19 | $-1.45 | $-1.51 | $-1.67 | $-1.86 | $-1.74 | $-1.59 | $-1.81 | $-1.55 | $-1.54 | $-1.61 | $-1.75 | $-1.78 | $-1.63 | $-1.72 | $-1.89 | $-2.21 | $-2.07 |
High Forecast | $0.91 | $0.84 | $0.20 | $0.03 | $0.02 | $-0.44 | $-0.67 | $-0.69 | $-0.72 | $-0.34 | $-0.89 | $-0.93 | $0.05 | $0.71 | $-1.25 | $-1.39 | $-1.55 | $-1.45 | $-1.59 | $-1.67 | $-1.43 | $-1.42 | $-1.48 | $-1.61 | $-1.64 | $-1.50 | $-1.59 | $-1.74 | $-2.04 | $-1.91 |
Low Forecast | $0.66 | $0.61 | $0.15 | $0.02 | $0.01 | $-0.60 | $-0.93 | $-0.95 | $-0.99 | $-1.29 | $-1.22 | $-1.27 | $-3.04 | $-2.06 | $-1.72 | $-1.91 | $-2.12 | $-1.99 | $-1.59 | $-2.11 | $-1.80 | $-1.79 | $-1.87 | $-2.04 | $-2.08 | $-1.90 | $-2.01 | $-2.20 | $-2.58 | $-2.42 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.82% | - | 0.84% | 0.90% | 1.90% | - | 1.11% | 1.40% | 1.12% | 1.00% | 0.98% | 1.17% | 1.34% | 0.90% | 0.86% | 1.12% | 0.93% |
Alnylam Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
WVE | Wave Life Sciences | $5.86 | $14.00 | 138.91% | Buy |
APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
PRQR | ProQR Therapeutics | $1.85 | $3.63 | 96.22% | Buy |
RARE | Ultragenyx Pharmaceutical | $58.74 | $108.14 | 84.10% | Buy |
BMRN | BioMarin Pharmaceutical | $84.90 | $111.41 | 31.22% | Buy |
MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
INCY | Incyte | $63.56 | $81.00 | 27.44% | Buy |
AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
EXEL | Exelixis | $26.46 | $28.00 | 5.82% | Buy |
KRYS | Krystal Biotech | $201.58 | $191.00 | -5.25% | Buy |
ALNY | Alnylam Pharmaceuticals | $265.27 | $250.16 | -5.70% | Buy |
UTHR | United Therapeutics | $339.12 | $312.50 | -7.85% | Buy |
HALO | Halozyme Therapeutics | $62.30 | $56.86 | -8.73% | Buy |
KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
ALNY Forecast FAQ
Is Alnylam Pharmaceuticals a good buy?
Yes, according to 21 Wall Street analysts, Alnylam Pharmaceuticals (ALNY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 16 'Buy' recommendations, accounting for 76.19% of ALNY's total ratings.
What is ALNY's price target?
Alnylam Pharmaceuticals (ALNY) average price target is $250.16 with a range of $96 to $400, implying a -5.70% from its last price of $265.27. The data is based on 21 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Alnylam Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for ALNY stock, the company can go down by -5.70% (from the last price of $265.27 to the average price target of $250.16), up by 50.79% based on the highest stock price target, and down by -63.81% based on the lowest stock price target.
Can Alnylam Pharmaceuticals stock reach $400?
ALNY's average twelve months analyst stock price target of $250.16 does not support the claim that Alnylam Pharmaceuticals can reach $400 in the near future.
What is Alnylam Pharmaceuticals's current price target trend?
3 Wall Street analysts forecast a $323.33 price target for Alnylam Pharmaceuticals (ALNY) this month, up 21.89% from its last price of $265.27. Compared to the last 3 and 12 months, the average price target increased by 12.53% and increased by 9.08%, respectively.
What are Alnylam Pharmaceuticals's analysts' financial forecasts?
Alnylam Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.53B (high $2.8B, low $2.2B), average EBITDA is $-1.935B (high $-1.685B, low $-2.146B), average net income is $-272M (high $-226M, low $-312M), average SG&A $2.67B (high $2.96B, low $2.33B), and average EPS is $-2.15 (high $-1.784, low $-2.459). ALNY's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.35B (high $3.72B, low $2.92B), average EBITDA is $-2.566B (high $-2.234B, low $-2.845B), average net income is $219.07M (high $250.09M, low $182.25M), average SG&A $3.54B (high $3.93B, low $3.09B), and average EPS is $1.73 (high $1.97, low $1.44).
Did the ALNY's actual financial results beat the analysts' financial forecasts?
Based on Alnylam Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $1.83B, beating the average analysts forecast of $1.48B by 23.68%. Apple's EBITDA was $-282M, missing the average prediction of $-1.081B by -73.89%. The company's net income was $-440M, missing the average estimation of $-766M by -42.51%. Apple's SG&A was $0, missing the average forecast of $1.39B by -100.00%. Lastly, the company's EPS was $0, missing the average prediction of $-5.808 by -100.00%. In terms of the last quarterly report (Sep 2023), Alnylam Pharmaceuticals's revenue was $750.53M, beating the average analysts' forecast of $396.76M by 89.17%. The company's EBITDA was $213.87M, missing the average prediction of $-304M by -170.43%. Alnylam Pharmaceuticals's net income was $147.75M, missing the average estimation of $-183M by -180.65%. The company's SG&A was $199.18M, missing the average forecast of $419.52M by -52.52%. Lastly, the company's EPS was $1.18, missing the average prediction of $-1.446 by -181.62%